mardi 19 juin 2018

Onco Actu du 19 juin 2018

1. Biologie

Ovarian cancer cells switched off by 'unusual' mechanism [Imperial College]

Study Suggests Well-Known Growth Suppressor Actually Fuels Lethal Brain Cancers [Cincinatti Children's]

Genomics offers new treatment options for infants with range of soft tissue tumours [Sanger Institute]

3.3 Prévention - Vaccins

New Gardasil ad campaign gets it (mostly) right. It shouldn’t have taken a decade [STAT]

4.1 Dép., diag. & prono. - Prostate

Wales 'behind' in technology to detect prostate cancer [BBC News]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

Myriad's BRACAnalysis CDx® Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Talazoparib in Metastatic Breast Cancer [Myriad]

5. Traitements

JAK Inhibitors Associated with Aggressive Lymphoma [ASH]

Biosimilars for Cancer Emerge as Patents on Widely Used Biological Drugs Expire [NCI]

5.12 Immunothérapies

How many PD-1 and PD-L1 checkpoint inhibitors do we need? [Pipeline Review]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

FDA hits Ziopharm CAR-T trial with clinical hold [FierceBiotech]

Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy [Ziopharm]

5.12.5 Immunothérapies - Pharma

CAR-T startup Allogene Therapeutics picks up veteran analyst Eric Schmidt as CFO [STAT]

5.12.8 Immunothérapies - Economie

Johns Hopkins spinout WindMIL grabs $32.5M to fuel its work on a next-gen approach to cell therapy [EndPoints]

5.2.2 Pharma - Fusions & Acquisitions

Roche bags full ownership of Foundation Medicine in $2.4B follow-up buyout [EndPoints]

Roche pays $2.4 billion for rest of cancer expert Foundation Medicine [Reuters]

Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology [Roche]

5.3 Traitements - FDA, EMA, NICE...

Budget Matters: Infrastructure to Support Robust Generic Drug Competition [FDA]

5.9.3 EHA

Bristol-Myers, AbbVie eye new use for myeloma drug Empliciti after phase 2 combo win [FiercePharma]

AbbVie unveils high undetectable disease rates for venetoclax/rituximab combo [PharmaTimes]

Daiichi says it’s ready to change the standard of care for acute myeloid leukemia — but it’s a work in progress [EndPoints]

Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyo’s Quizartinib Significantly Prolongs Overall Survival as Single Agent Compared to Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations [Daiichi-Sankayo]

6.10 Politiques

NHS funding: New money for England is a start, but it must be spent wisely [Cancer Research UK]

6.5 Médecines alternatives

ASCO endorses the integration of quackery into breast cancer care [Science-based Medicine]

6.9 Controverses

Why the Medical Research Grant System Could Be Costing Us Great Ideas [NY Times]